640 related articles for article (PubMed ID: 28548288)
1. Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.
Blouin S; Fratzl-Zelman N; Glorieux FH; Roschger P; Klaushofer K; Marini JC; Rauch F
J Bone Miner Res; 2017 Sep; 32(9):1884-1892. PubMed ID: 28548288
[TBL] [Abstract][Full Text] [Related]
2. Alterations of bone material properties in growing Ifitm5/BRIL p.S42 knock-in mice, a new model for atypical type VI osteogenesis imperfecta.
Hedjazi G; Guterman-Ram G; Blouin S; Schemenz V; Wagermaier W; Fratzl P; Hartmann MA; Zwerina J; Fratzl-Zelman N; Marini JC
Bone; 2022 Sep; 162():116451. PubMed ID: 35654352
[TBL] [Abstract][Full Text] [Related]
3. Type V OI primary osteoblasts display increased mineralization despite decreased COL1A1 expression.
Reich A; Bae AS; Barnes AM; Cabral WA; Hinek A; Stimec J; Hill SC; Chitayat D; Marini JC
J Clin Endocrinol Metab; 2015 Feb; 100(2):E325-32. PubMed ID: 25387264
[TBL] [Abstract][Full Text] [Related]
4. Increased Osteocyte Lacunae Density in the Hypermineralized Bone Matrix of Children with Osteogenesis Imperfecta Type I.
Mähr M; Blouin S; Behanova M; Misof BM; Glorieux FH; Zwerina J; Rauch F; Hartmann MA; Fratzl-Zelman N
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925942
[TBL] [Abstract][Full Text] [Related]
5. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
6. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
[TBL] [Abstract][Full Text] [Related]
7. Type V osteogenesis imperfecta: a new form of brittle bone disease.
Glorieux FH; Rauch F; Plotkin H; Ward L; Travers R; Roughley P; Lalic L; Glorieux DF; Fassier F; Bishop NJ
J Bone Miner Res; 2000 Sep; 15(9):1650-8. PubMed ID: 10976985
[TBL] [Abstract][Full Text] [Related]
8. Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone.
Fratzl-Zelman N; Schmidt I; Roschger P; Roschger A; Glorieux FH; Klaushofer K; Wagermaier W; Rauch F; Fratzl P
Bone; 2015 Apr; 73():233-41. PubMed ID: 25554599
[TBL] [Abstract][Full Text] [Related]
9. IFITM5 pathogenic variant causes osteogenesis imperfecta V with various phenotype severity in Ukrainian and Vietnamese patients.
Zhytnik L; Maasalu K; Duy BH; Pashenko A; Khmyzov S; Reimann E; Prans E; Kõks S; Märtson A
Hum Genomics; 2019 Jun; 13(1):25. PubMed ID: 31159867
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
Kanno J; Saito-Hakoda A; Kure S; Fujiwara I
J Bone Miner Metab; 2018 May; 36(3):344-351. PubMed ID: 28528406
[TBL] [Abstract][Full Text] [Related]
11. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.
Glorieux FH; Ward LM; Rauch F; Lalic L; Roughley PJ; Travers R
J Bone Miner Res; 2002 Jan; 17(1):30-8. PubMed ID: 11771667
[TBL] [Abstract][Full Text] [Related]
12. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
13. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
14. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
15. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
16. CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII.
Fratzl-Zelman N; Morello R; Lee B; Rauch F; Glorieux FH; Misof BM; Klaushofer K; Roschger P
Bone; 2010 Mar; 46(3):820-6. PubMed ID: 19895918
[TBL] [Abstract][Full Text] [Related]
17. Combination of osteogenesis imperfecta and hypophosphatasia in three children with multiple fractures, low bone mass and severe osteomalacia, a challenge for therapeutic management.
Fratzl-Zelman N; Linglart A; Bin K; Rauch F; Blouin S; Coutant R; Donzeau A
Eur J Med Genet; 2023 Nov; 66(11):104856. PubMed ID: 37758163
[TBL] [Abstract][Full Text] [Related]
18. A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor.
Farber CR; Reich A; Barnes AM; Becerra P; Rauch F; Cabral WA; Bae A; Quinlan A; Glorieux FH; Clemens TL; Marini JC
J Bone Miner Res; 2014 Jun; 29(6):1402-11. PubMed ID: 24519609
[TBL] [Abstract][Full Text] [Related]
19. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Zacharin M; Bateman J
J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
[TBL] [Abstract][Full Text] [Related]
20. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
